GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Inventories, Inventories Adjustments

NovMetaPharma Co (XKRX:229500) Inventories, Inventories Adjustments : ₩0.00 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Inventories, Inventories Adjustments?

NovMetaPharma Co's Inventories, Inventories Adjustments for the quarter that ended in Dec. 2023 was ₩0.00 Mil.


NovMetaPharma Co Inventories, Inventories Adjustments Historical Data

The historical data trend for NovMetaPharma Co's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Inventories, Inventories Adjustments Chart

NovMetaPharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Inventories Adjustments
Get a 7-Day Free Trial Premium Member Only - -0.64 - - -

NovMetaPharma Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only - -0.64 - - -

NovMetaPharma Co Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


NovMetaPharma Co (XKRX:229500) Business Description

Industry
Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co (XKRX:229500) Headlines

No Headlines